Carlyle Pays Almost $500m For A Fifth Of Piramal Pharma
Carlyle's 20% Stake Gives Piramal Pharma 'War Chest' For Growth
Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
